ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer

Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab treatment. Beside ADAM17, ADAM10 is the other well characterized ADAM protease...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldinger, Katharina, Generali, Daniele, Kramer-Marek, Gabriela, Gijsen, Merel, Ng, Tzi Bun, Wong, Jack Ho, Strina, Carla, Cappelletti, Mariarosa, Andreis, Daniele, Li, Ji-Liang, Bridges, Esther, Turley, Helen, Leek, Russell, Roxanis, Ioannis, Capala, Jacek, Murphy, Gillian, Harris, Adrian L., Kong, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196152/
https://www.ncbi.nlm.nih.gov/pubmed/24952873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196152/
https://www.ncbi.nlm.nih.gov/pubmed/24952873

Ejemplares similares